AARD 8-K: ARD-101/ARD-201 and ObesityWeek 2025 webinar deck

Rhea-AI Filing Summary

Aardvark Therapeutics filed an 8-K announcing it hosted an investor webinar on November 5, 2025 to review its ARD-101 and ARD-201 programs and its ObesityWeek 2025 presentations. The slide deck used is posted on the company’s website and is filed as Exhibit 99.1. The presentation is current as of November 5, 2025, and the company disclaims any obligation to update the material.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 11/05/2025 - 06:11 PM Learn about SEC filing dates

false000177485700017748572025-11-052025-11-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 05, 2025

Aardvark Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-42513	82-1606367
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
4370 La Jolla Village Drive, Suite 1050
San Diego, California				92122
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 225-7696

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		AARD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On November 5, 2025, Aardvark Therapeutics, Inc. (the “Company”) hosted an investor webinar to review its ARD-101 and ARD-201 programs, as well as its ObesityWeek 2025 presentations. A copy of the presentation used in connection with the webinar will be posted to the Company’s website and is also filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference into this Item 8.01. The presentation is current as of November 5, 2025, and the Company disclaims any obligation to update this material in the future.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Presentation- ObesityWeek Investor Webinar, dated November 5, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			AARDVARK THERAPEUTICS, INC.
Date:	November 5, 2025	By:	/s/ Tien-Li Lee, M.D.
			Tien-Li Lee, M.D. Chief Executive Officer

FAQ

What did Aardvark Therapeutics (AARD) announce in this 8-K?

The company hosted an investor webinar reviewing ARD-101, ARD-201, and ObesityWeek 2025 presentations, and filed the slide deck as Exhibit 99.1.

When was the AARD investor webinar held?

The investor webinar took place on November 5, 2025.

Which programs were discussed by Aardvark Therapeutics (AARD)?

The webinar reviewed the company’s ARD-101 and ARD-201 programs.

Where can I access the AARD investor webinar presentation?

The presentation is posted on the company’s website and filed as Exhibit 99.1.

Does the 8-K include financial results for AARD?

No. It reports the occurrence of the investor webinar and the availability of the presentation materials.

Is the presentation being updated by AARD?

The company states the presentation is current as of November 5, 2025 and disclaims any obligation to update it.